Progesterone_NN receptors_NNS --_: animal_JJ models_NNS and_CC cell_NN signaling_VBG in_IN breast_NN cancer_NN :_: The_DT role_NN of_IN oestrogen_NN and_CC progesterone_NN receptors_NNS in_IN human_JJ mammary_JJ development_NN and_CC tumorigenesis_NN Abstract_NP |_SYM A_DT relatively_RB small_JJ number_NN of_IN cells_NNS in_IN the_DT normal_JJ human_JJ mammary_JJ gland_NN express_JJ receptors_NNS for_IN oestrogen_NN and_CC progesterone_NN (_( ER_NP and_CC PR_NP )_) ,_, and_CC there_EX is_VBZ almost_RB complete_JJ dissociation_NN between_IN steroid_NN receptor_NN expression_NN and_CC proliferation_NN ._SENT Increased_VBN expression_NN of_IN the_DT ER_JJ alpha_NN (_( ERalpha_NP )_) and_CC loss_NN of_IN the_DT inverse_JJ relationship_NN between_IN receptor_NN expression_NN and_CC proliferation_NN occur_VBP at_IN the_DT very_RB earliest_JJS stages_NNS of_IN tumorigenesis_NN ,_, implying_VBG that_DT dysregulation_NN of_IN ERalpha_NP expression_NN contributes_VBZ to_TO breast_VB tumour_NN formation_NN ._SENT There_EX is_VBZ evidence_NN also_RB for_IN alterations_NNS in_IN the_DT ratio_NN between_IN the_DT two_CD PR_NP isoforms_NNS in_IN premalignant_JJ breast_NN lesions_NNS ._SENT Elucidation_NN of_IN the_DT factors_NNS mediating_VBG the_DT effects_NNS of_IN oestradiol_NN and_CC progesterone_NN on_IN development_NN of_IN the_DT normal_JJ breast_NN and_CC of_IN the_DT mechanisms_NNS by_IN which_WDT expression_NN of_IN the_DT ERalpha_NP and_CC the_DT PR_NP isoforms_NNS is_VBZ controlled_VBN could_MD identify_VB new_JJ targets_NNS for_IN breast_NN cancer_NN prevention_NN and_CC improved_VBN prediction_NN of_IN breast_NN cancer_NN risk_NN ._SENT breast_NN tumours_NNS ,_, normal_JJ mammary_JJ epithelium_NN ,_, oestrogen_NN receptor_NN ,_, progesterone_NN receptor_NN ,_, The_DT human_JJ mammary_JJ epithelium_NN is_VBZ the_DT tissue_NN from_IN which_WDT most_JJS breast_NN tumours_NNS arise_VBP ._SENT Understanding_VBG how_WRB processes_VBZ such_JJ as_IN proliferation_NN and_CC differentiation_NN of_IN the_DT epithelium_NN are_VBP controlled_VBN by_IN the_DT ovarian_JJ steroids_NNS oestradiol_NN and_CC progesterone_NN may_MD lead_VB to_TO an_DT increased_VBN understanding_NN of_IN the_DT carcinogenic_JJ process_NN ._SENT The_DT present_JJ article_NN reviews_VBZ some_DT of_IN what_WP is_VBZ known_VBN about_IN the_DT involvement_NN of_IN the_DT receptors_NNS for_IN oestradiol_NN and_CC progesterone_NN in_IN the_DT normal_JJ mammary_JJ gland_NN and_CC in_IN tumorigenesis_NN ._SENT The_DT mammary_JJ gland_NN is_VBZ not_RB completely_RB formed_VBN at_IN birth_NN ,_, but_CC begins_VBZ to_TO develop_VB in_IN early_JJ puberty_NN when_WRB the_DT primitive_JJ ductal_JJ structures_NNS enlarge_VBP and_CC branch_NN ._SENT Once_IN ovulatory_JJ menstrual_JJ cycles_NNS have_VBP begun_VBN ,_, branching_VBG of_IN the_DT ductal_JJ system_NN becomes_VBZ more_RBR complex_JJ and_CC lobular_JJ structures_NNS form_NN at_IN the_DT ends_NNS of_IN the_DT terminal_JJ ducts_NNS to_TO produce_VB terminal_JJ ductal_JJ lobular_JJ units_NNS (_( TDLUs_NP )_) ,_, which_WDT become_VBP more_JJR complex_NN with_IN successive_JJ menstrual_JJ cycles_NNS ._SENT During_IN early_JJ pregnancy_NN ,_, there_EX is_VBZ another_DT burst_NN of_IN activity_NN in_IN which_WDT the_DT ductal_JJ trees_NNS expand_VBP further_RBR and_CC the_DT number_NN of_IN ductules_NNS within_IN the_DT TDLUs_NP increases_NNS greatly_RB ._SENT These_DT ductules_NNS differentiate_VBP to_TO synthesise_VB and_CC secrete_VB milk_NN in_IN late_JJ pregnancy_NN and_CC subsequent_JJ lactation_NN ._SENT The_DT entire_JJ ductal_JJ system_NN of_IN the_DT human_JJ mammary_JJ gland_NN is_VBZ lined_VBN by_IN a_DT continuous_JJ layer_NN of_IN luminal_JJ epithelial_JJ cells_NNS that_WDT is_VBZ ,_, in_IN turn_NN ,_, surrounded_VBN by_IN a_DT layer_NN of_IN myoepithelial_JJ cells_NNS ._SENT These_DT myoepithelial_JJ cells_NNS are_VBP in_IN direct_JJ contact_NN with_IN the_DT basement_NN membrane_NN ,_, and_CC the_DT TDLUs_NP are_VBP surrounded_VBN by_IN delimiting_VBG fibroblasts_NNS and_CC embedded_VBN in_IN a_DT specialised_VBN intralobular_JJ stroma_NN ._SENT Histological_JJ studies_NNS have_VBP shown_VBN that_DT most_RBS human_JJ breast_NN tumours_NNS appear_VBP to_TO be_VB derived_VBN from_IN TDLUs_NP and_CC have_VB morphological_JJ characteristics_NNS of_IN luminal_JJ epithelial_JJ cells_NNS (_( reviewed_VBN in_IN )_) ._SENT Moreover_RB ,_, most_RBS human_JJ breast_NN tumours_NNS retain_VBP the_DT biochemical_JJ features_NNS of_IN luminal_JJ cells_NNS in_IN that_WDT they_PP express_VBP the_DT appropriate_JJ cytokeratins_NNS and_CC membrane_NN antigens_NNS such_JJ as_IN MUC-1_NP ._SENT Human_JJ tumours_NNS also_RB contain_VBP receptors_NNS for_IN oestradiol_NN and_CC progesterone_NN that_IN ,_, in_IN the_DT normal_JJ breast_NN ,_, are_VBP expressed_VBN only_RB in_IN the_DT luminal_JJ epithelial_JJ cell_NN compartment_NN ._SENT Luminal_JJ epithelial_JJ cells_NNS must_MD therefore_RB be_VB regarded_VBN as_IN the_DT primary_JJ targets_NNS for_IN malignant_JJ transformation_NN and_CC subsequent_JJ tumour_NN formation_NN ._SENT The_DT process_NN of_IN breast_NN tumorigenesis_NN is_VBZ thought_VBN to_TO result_VB from_IN a_DT '_'' benign_JJ to_TO malignant_JJ '_'' progression_NN in_IN which_WDT the_DT accumulation_NN of_IN multiple_JJ genetic_JJ changes_NNS allows_VBZ evolution_NN from_IN normal_JJ breast_NN epithelium_NN through_IN benign_JJ proliferative_JJ lesions_NNS to_TO atypical_JJ proliferative_JJ lesions_NNS ,_, and_CC then_RB to_TO carcinoma_NN in_IN situ_NN and_CC frankly_RB invasive_JJ tumours_NNS ._SENT This_DT progression_NN is_VBZ elegantly_RB reviewed_VBN by_IN Allred_NP and_CC colleagues_NNS ,_, who_WP report_VBP that_IN the_DT lesions_NNS associated_VBN with_IN the_DT greatest_JJS risk_NN of_IN invasive_JJ breast_NN cancer_NN are_VBP hyperplasia_NN of_IN usual_JJ type_NN ,_, atypical_JJ ductal_JJ hyperplasia_NN ,_, ductal_JJ carcinoma_NN in_IN situ_NN (_( DCIS_NP )_) and_CC lobular_JJ carcinoma_NN in_IN situ_NN ._SENT The_DT clinical_JJ and_CC epidemiological_JJ evidence_NN for_IN an_DT obligate_JJ role_NN of_IN oestrogen_NN in_IN human_JJ mammary_JJ gland_NN development_NN and_CC tumorigenesis_NN is_VBZ considerable_JJ ._SENT There_EX is_VBZ complete_JJ failure_NN of_IN breast_NN development_NN in_IN the_DT absence_NN of_IN intact_JJ ovarian_JJ function_NN ,_, and_CC oestradiol-replacement_NN therapy_NN is_VBZ necessary_JJ to_TO induce_VB breast_NN development_NN ._SENT Increased_VBN exposure_NN to_TO the_DT fluctuating_VBG levels_NNS of_IN oestradiol_NN of_IN the_DT menstrual_JJ cycle_NN through_IN early_JJ menarche_NN ,_, late_JJ menopause_NN or_CC a_DT late_JJ ,_, first_JJ ,_, full-term_NN pregnancy_NN increases_VBZ breast_NN cancer_NN risk_NN ,_, as_RB does_VBZ use_NN of_IN exogenous_JJ oestrogens_NNS in_IN the_DT form_NN of_IN the_DT oral_JJ contraceptive_JJ pill_NN or_CC hormone_NN replacement_NN therapy_NN ._SENT More_RBR compellingly_RB ,_, treatment_NN with_IN anti-oestrogens_NNS reduces_VBZ the_DT incidence_NN of_IN breast_NN cancer_NN in_IN high-risk_JJ women_NNS ._SENT The_DT obligate_JJ role_NN for_IN oestradiol_NN in_IN mammary_JJ gland_NN development_NN and_CC tumour_NN formation_NN has_VBZ been_VBN confirmed_VBN in_IN studies_NNS on_IN mice_NNS where_WRB the_DT gene_NN for_IN the_DT ERalpha_NP has_VBZ been_VBN knocked_VBN out_RP ._SENT The_DT mammary_JJ glands_NNS in_IN these_DT ERalpha_NP knockout_NN mice_NNS comprise_VBP rudimentary_JJ ducts_NNS confined_VBN to_TO the_DT nipple_NN area_NN ,_, which_WDT cannot_MD be_VB induced_VBN to_TO develop_VB further_JJR with_IN oestradiol_NN treatment_NN and_CC which_WDT are_VBP resistant_JJ to_TO malignant_JJ transformation_NN following_VBG transduction_NN with_IN oncogenes_NNS ._SENT There_EX is_VBZ far_RB less_JJR evidence_NN for_IN a_DT role_NN of_IN progesterone_NN in_IN human_JJ breast_NN development_NN ._SENT Studies_NNS on_IN mouse_NN models_NNS in_IN which_WDT the_DT PR_NP has_VBZ been_VBN knocked_VBN out_RP suggest_VBP that_IN ,_, whereas_IN oestradiol_NN stimulates_VBZ ductal_JJ elongation_NN and_CC PR_NP expression_NN ,_, progesterone_NN induces_VBZ lobuloalveolar_JJ development_NN ._SENT Generally_RB ,_, it_PP is_VBZ assumed_VBN that_IN progesterone_NN plays_VBZ a_DT similar_JJ role_NN in_IN the_DT human_JJ breast_NN and_CC stimulates_VBZ TDLU_NP formation_NN and_CC expansion_NN during_IN puberty_NN and_CC pregnancy_NN ._SENT As_RB far_RB as_RB is_VBZ known_VBN this_DT has_VBZ never_RB been_VBN demonstrated_VBN ,_, although_IN this_DT might_MD be_VB because_IN it_PP is_VBZ almost_RB impossible_JJ to_TO study_VB human_JJ breast_NN tissue_NN at_IN these_DT stages_NNS of_IN development_NN ._SENT As_RB far_RB as_IN a_DT role_NN for_IN progesterone_NN in_IN breast_NN tumorigenesis_NN is_VBZ concerned_VBN ,_, there_EX are_VBP now_RB some_DT data_NNS suggesting_VBG that_IN exogenous_JJ progestins_NNS taken_VBN in_IN the_DT form_NN of_IN combined_JJ hormone_NN replacement_NN therapy_NN increase_VB the_DT risk_NN of_IN postmenopausal_JJ breast_NN cancer_NN to_TO a_DT greater_JJR extent_NN than_IN use_NN of_IN oestrogen_NN replacement_NN therapy_NN alone_RB ._SENT Steroid_NN hormones_NNS such_JJ as_IN oestradiol_NN and_CC progesterone_NN are_VBP lipophilic_JJ and_CC they_PP enter_VBP cells_NNS and_CC their_PP$ nuclei_NNS primarily_RB by_IN diffusing_VBG through_IN the_DT plasma_NN and_CC nuclear_JJ membranes_NNS ._SENT Once_RB in_IN the_DT nucleus_NN ,_, the_DT steroids_NNS encounter_VBP proteins_NNS known_VBN as_IN receptors_NNS because_IN they_PP bind_VBP their_PP$ cognate_JJ ligands_NNS with_IN high_JJ affinity_NN and_CC specificity_NN ._SENT There_EX are_VBP two_CD receptors_NNS for_IN oestradiol_NN ,_, the_DT ERalpha_NP and_CC the_DT ERbeta_NP ._SENT Both_CC these_DT ERs_NNS are_VBP members_NNS of_IN the_DT steroid/thyroid_JJ hormone_NN nuclear_JJ receptor_NN superfamily_NN and_CC both_DT may_MD be_VB described_VBN as_IN ligand-dependent_JJ nuclear_JJ transcription_NN factors_NNS ._SENT The_DT ER_JJ proteins_NNS have_VBP the_DT modular_JJ structure_NN that_WDT typifies_VBZ the_DT nuclear_JJ receptor_NN superfamily_NN ,_, which_WDT includes_VBZ domains_NNS that_WDT mediate_VBP binding_VBG to_TO ligands_NNS and_CC to_TO DNA_NP ._SENT Although_IN the_DT two_CD ERs_NNS are_VBP homologous_JJ in_IN their_PP$ DNA-binding_NN and_CC steroid-binding_NN domains_NNS ,_, the_DT ERbeta_NP gene_NN is_VBZ smaller_JJR ,_, it_PP has_VBZ a_DT different_JJ chromosomal_JJ location_NN and_CC it_PP encodes_VBZ a_DT shorter_JJR protein_NN ._SENT The_DT distinctly_RB different_JJ but_CC overlapping_JJ tissue_NN distribution_NN of_IN the_DT ERbeta_NP compared_VBN with_IN the_DT ERalpha_NP suggests_VBZ that_IN it_PP might_MD mediate_VB some_DT of_IN the_DT non-classical_JJ effects_NNS of_IN oestrogens_NNS and_CC anti-oestrogens_NNS ._SENT Alternatively_RB ,_, the_DT results_NNS of_IN experimental_JJ studies_NNS suggest_VBP that_IN the_DT ERbeta_NP might_MD interact_VB with_IN and_CC negatively_RB modulate_VBP the_DT actions_NNS of_IN the_DT ERalpha_NP ._SENT Progesterone_NN also_RB has_VBZ two_CD receptors_NNS ,_, PRA_NP and_CC PRB_NP ._SENT Unlike_IN the_DT ERs_NN ,_, however_RB ,_, these_DT two_CD receptors_NNS are_VBP transcribed_VBN from_IN the_DT same_JJ gene_NN via_IN alternative_JJ promoter_NN usage_NN ._SENT PRB_NP is_VBZ longer_RBR than_IN PRA_NP as_IN it_PP contains_VBZ an_DT additional_JJ 164_CD amino_NN acids_NNS at_IN its_PP$ N-terminal_JJ ,_, but_CC otherwise_RB the_DT two_CD proteins_NNS are_VBP identical_JJ ._SENT PRA_NP and_CC PRB_NP also_RB are_VBP members_NNS of_IN the_DT steroid/thyroid_JJ hormone_NN nuclear_JJ receptor_NN superfamily_NN ,_, and_CC they_PP function_VBP as_IN ligand-dependent_JJ nuclear_JJ transcription_NN factors_NNS ._SENT It_PP has_VBZ been_VBN suggested_VBN that_IN PRB_NP is_VBZ the_DT major_JJ activator_NN of_IN gene_NN transcription_NN and_CC that_IN PRA_NP is_VBZ a_DT repressor_NN of_IN PRB_NN activity_NN ._SENT However_RB ,_, more_JJR recent_JJ studies_NNS on_IN breast_NN cancer_NN cells_NNS engineered_VBN to_TO express_VB either_DT PRA_NP or_CC PRB_NP alone_RB or_CC on_IN mice_NNS in_IN which_WDT the_DT isoforms_NNS have_VBP been_VBN selectively_RB deleted_VBN suggest_VBP that_IN PRA_NP as_RB well_RB as_IN PRB_NP can_MD activate_VB gene_NN transcription_NN ._SENT Moreover_RB ,_, the_DT two_CD isoforms_NNS can_MD be_VB differentiated_VBN in_IN terms_NNS of_IN the_DT profile_NN of_IN genes_NNS that_IN they_PP can_MD activate_VB and_CC by_IN the_DT fact_NN that_IN PRB_NP ,_, but_CC not_RB PRA_NP ,_, mediates_VBZ the_DT effects_NNS of_IN progesterone_NN on_IN mouse_NN mammary_JJ gland_NN development_NN ._SENT Most_JJS data_NNS on_IN ER_NP and_CC PR_NP expression_NN in_IN the_DT normal_JJ human_JJ breast_NN have_VBP been_VBN obtained_VBN in_IN the_DT course_NN of_IN studies_NNS on_IN tissue_NN from_IN adult_JJ women_NNS who_WP are_VBP neither_RB pregnant_JJ nor_CC lactating_VBG ._SENT These_DT studies_NNS show_VBP that_IN ERalpha_NP is_VBZ expressed_VBN in_IN approximately_RB 15_CD --_: 30_CD %_NN of_IN luminal_JJ epithelial_JJ cells_NNS and_CC not_RB at_IN all_DT in_IN any_DT of_IN the_DT other_JJ cell_NN types_NNS within_IN the_DT human_JJ breast_NN ._SENT Studies_NNS on_IN the_DT expression_NN of_IN ERbeta_NP in_IN either_DT normal_JJ or_CC malignant_JJ human_JJ breast_NN epithelium_NN have_VBP been_VBN hampered_VBN by_IN a_DT lack_NN of_IN antibodies_NNS that_WDT can_MD reliably_RB detect_VB the_DT protein_NN in_IN sections_NNS of_IN formalin-fixed_JJ ,_, paraffin-embedded_JJ tissue_NN ._SENT Such_JJ antibodies_NNS have_VBP recently_RB been_VBN developed_VBN ,_, however_RB ,_, and_CC initial_JJ studies_NNS indicate_VBP that_IN the_DT ERbeta_NP is_VBZ expressed_VBN in_IN most_RBS luminal_JJ epithelial_JJ and_CC myoepithelial_JJ cells_NNS ,_, as_RB well_RB as_IN being_VBG detectable_JJ in_IN fibroblasts_NNS and_CC other_JJ stromal_JJ cells_NNS within_IN the_DT normal_JJ human_JJ breast_NN ._SENT Unfortunately_RB ,_, this_DT widespread_JJ distribution_NN is_VBZ not_RB very_RB informative_JJ as_IN regards_NNS the_DT function_NN of_IN the_DT ERbeta_NP in_IN the_DT normal_JJ breast_NN ._SENT The_DT results_NNS of_IN studies_NNS on_IN mice_NNS in_IN which_WDT the_DT ERbeta_NP has_VBZ been_VBN deleted_VBN are_VBP similarly_RB uninformative_JJ as_IN the_DT mammary_JJ glands_NNS develop_VBP normally_RB in_IN these_DT mice_NNS and_CC they_PP appear_VBP to_TO have_VB no_DT difficulty_NN in_IN nursing_VBG their_PP$ young_JJ ._SENT These_DT data_NNS thus_RB suggest_VBP that_IN ,_, despite_IN its_PP$ more_JJR restricted_JJ pattern_NN of_IN expression_NN ,_, the_DT ERalpha_NP is_VBZ the_DT key_JJ mediator_NN of_IN oestradiol_NN action_NN in_IN the_DT normal_JJ mammary_JJ gland_NN and_CC suggest_VBP that_IN further_JJR studies_NNS are_VBP required_VBN to_TO establish_VB the_DT role_NN of_IN ERbeta_NP ._SENT Most_JJS of_IN the_DT investigations_NNS where_WRB immunohistochemistry_NN was_VBD used_VBN to_TO determine_VB the_DT level_NN and_CC distribution_NN of_IN PR_NP expression_NN in_IN the_DT normal_JJ human_JJ breast_NN were_VBD carried_VBN out_RP before_IN reagents_NNS capable_JJ of_IN distinguishing_VBG the_DT two_CD isoforms_NNS became_VBD available_JJ ._SENT Nevertheless_RB ,_, these_DT studies_NNS showed_VBD that_IN ,_, like_IN the_DT ERalpha_NP ,_, the_DT PR_NP was_VBD present_JJ in_IN 15_CD --_: 30_CD %_NN of_IN luminal_JJ epithelial_JJ cells_NNS and_CC not_RB elsewhere_RB in_IN the_DT breast_NN ._SENT Dual-label_NP immunofluorescent_JJ techniques_NNS have_VBP been_VBN used_VBN to_TO show_VB that_IN all_DT cells_NNS expressing_VBG the_DT PR_NP also_RB contain_VBP the_DT ERalpha_NP ._SENT In_IN contrast_NN ,_, steroid_NN receptor-expressing_NN cells_NNS are_VBP separate_JJ from_IN ,_, but_CC often_RB adjacent_JJ to_TO ,_, these_DT labelled_VBN with_IN markers_NNS of_IN proliferation_NN ._SENT This_DT dissociation_NN between_IN steroid_NN receptor_NN expression_NN and_CC proliferation_NN has_VBZ been_VBN confirmed_VBN by_IN other_JJ groups_NNS in_IN both_DT human_JJ breast_NN and_CC in_IN rodent_NN mammary_JJ glands_NNS ._SENT The_DT current_JJ hypothesis_NN is_VBZ that_IN oestradiol_NN and/or_CC progesterone_NN controls_VBZ the_DT proliferative_JJ activity_NN of_IN luminal_JJ epithelial_JJ cells_NNS indirectly_RB in_IN a_DT mechanism_NN where_WRB the_DT receptor-containing_NN cells_NNS act_NN as_RB '_POS sensors_NNS '_'' that_WDT secrete_VBP positive_JJ or_CC negative_JJ paracrine_NN and/or_CC juxtacrine_NN growth_NN factors_NNS ,_, according_VBG to_TO the_DT prevailing_JJ oestradiol/progesterone_NN concentrations_NNS ,_, to_TO influence_VB the_DT activity_NN of_IN nearby_JJ division-competent_JJ cells_NNS ._SENT This_DT would_MD attenuate_VB the_DT sensitivity_NN of_IN the_DT breast_NN epithelium_NN to_TO steroid_NN hormones_NNS such_PDT that_DT proliferation_NN will_MD occur_VB only_RB when_WRB a_DT sufficient_JJ concentration_NN of_IN positive_JJ growth_NN factors_NNS has_VBZ accumulated_VBN ._SENT This_DT might_MD be_VB achieved_VBN only_RB after_IN prolonged_JJ exposure_NN to_TO high_JJ levels_NNS of_IN steroid_NN and_CC possibly_RB other_JJ hormones_NNS ,_, as_RB in_IN early_JJ pregnancy_NN ,_, and_CC may_MD be_VB a_DT mechanism_NN for_IN preventing_VBG excessive_JJ proliferative_JJ activity_NN at_IN other_JJ times_NNS ._SENT Increased_VBN ERalpha_NP expression_NN may_MD be_VB one_CD of_IN the_DT very_RB earliest_JJS changes_NNS occurring_VBG in_IN the_DT tumorigenic_JJ process_NN ._SENT Khan_NP and_CC colleagues_NNS have_VBP shown_VBN increased_VBN ERalpha_NP expression_NN in_IN normal_JJ epithelium_NN taken_VBN from_IN tumour-bearing_NN breasts_NNS ._SENT In_IN addition_NN ,_, ERalpha_NP expression_NN is_VBZ higher_JJR in_IN the_DT breast_NN tissue_NN of_IN women_NNS from_IN a_DT population_NN at_IN high_JJ risk_NN of_IN breast_NN cancer_NN compared_VBN with_IN that_DT in_IN the_DT tissue_NN of_IN Japanese_JJ women_NNS who_WP have_VBP a_DT relatively_RB low_JJ risk_NN of_IN the_DT disease_NN ._SENT ERalpha_NN expression_NN is_VBZ increased_VBN at_IN the_DT very_RB earliest_JJS stages_NNS of_IN ductal_JJ hyperplasia_NN and_CC increases_NNS still_RB further_RBR with_IN increasing_VBG atypia_NN ,_, such_PDT that_DT most_JJS cells_NNS in_IN atypical_JJ ductal_JJ hyperplasias_NNS and_CC in_IN DCIS_NP of_IN low_JJ and_CC intermediate_JJ nuclear_JJ grade_NN contain_VBP the_DT ERalpha_NP ._SENT There_EX are_VBP fewer_JJR ERalpha-positive_JJ cells_NNS in_IN DCIS_NP of_IN high_JJ nuclear_JJ grade_NN ,_, but_CC the_DT expression_NN of_IN markers_NNS such_JJ as_IN c-erbB-2/HER-2_NP suggests_VBZ that_IN these_DT lesions_NNS form_VBP a_DT different_JJ pathway_NN to_TO invasive_JJ cancer_NN ._SENT As_IN ERalpha_NP expression_NN increases_NNS ,_, the_DT inverse_JJ relationship_NN between_IN receptor_NN expression_NN and_CC proliferation_NN becomes_VBZ dysregulated_JJ ._SENT There_EX are_VBP increasing_VBG numbers_NNS of_IN cells_NNS expressing_VBG both_CC the_DT ERalpha_NP and_CC the_DT Ki67_JJ proliferation-associated_JJ antigen_NN with_IN progression_NN toward_IN malignancy_NN ,_, and_CC this_DT is_VBZ another_DT early_JJ change_NN associated_VBN with_IN the_DT process_NN of_IN breast_NN tumorigenesis_NN ._SENT Interestingly_RB ,_, a_DT proportion_NN of_IN hyperplasias_NNS of_IN usual_JJ type_NN also_RB contain_VBP proliferating_VBG ERalpha-positive_JJ cells_NNS ,_, and_CC it_PP remains_VBZ to_TO be_VB seen_VBN whether_IN these_DT lesions_NNS are_VBP the_DT ones_NNS that_WDT progress_VBP to_TO invasive_JJ tumours_NNS ._SENT Approximately_RB 70_CD %_NN of_IN invasive_JJ breast_NN carcinomas_NNS contain_VBP the_DT ERalpha_NP ,_, and_CC preliminary_JJ studies_NNS indicate_VBP that_IN most_JJS of_IN these_DT tumours_NNS contain_VBP ERalpha-positive_JJ ,_, proliferating_VBG cells_NNS ._SENT Clearly_RB ,_, patients_NNS whose_WP$ invasive_JJ tumours_NNS contain_VBP the_DT ERalpha_NP are_VBP suitable_JJ for_IN endocrine_JJ therapy_NN ,_, but_CC there_EX is_VBZ no_DT evidence_NN that_IN dysregulation_NN of_IN the_DT relationship_NN between_IN receptor_NN expression_NN and_CC proliferation_NN has_VBZ any_DT influence_NN on_IN their_PP$ response_NN ._SENT This_DT is_VBZ in_IN keeping_VBG with_IN the_DT suggestion_NN that_IN dysregulation_NN is_VBZ an_DT important_JJ step_NN in_IN early_JJ tumorigenesis_NN but_CC is_VBZ less_RBR important_JJ at_IN later_JJR stages_NNS ._SENT There_EX are_VBP some_DT data_NNS showing_VBG that_DT ERbeta_NP expression_NN is_VBZ downregulated_JJ in_IN lesions_NNS such_JJ as_IN atypical_JJ ductal_JJ hyperplasia_NN and_CC DCIS_NP when_WRB compared_VBN with_IN that_DT in_IN normal_JJ breast_NN epithelium_NN ._SENT The_DT same_JJ group_NN has_VBZ shown_VBN that_IN the_DT receptor_NN is_VBZ inversely_RB correlated_VBN with_IN proliferation_NN and_CC that_IN the_DT ratio_NN between_IN the_DT ERalpha_NP and_CC the_DT ERbeta_NP increases_NNS with_IN increasing_VBG atypia_NN ._SENT This_DT is_VBZ consistent_JJ with_IN the_DT suggestion_NN that_IN the_DT ERbeta_NP negatively_RB modulates_VBZ the_DT effects_NNS of_IN the_DT ERalpha_NP ._SENT The_DT data_NNS with_IN regard_NN to_TO ERbeta_NP expression_NN in_IN invasive_JJ tumours_NNS and_CC its_PP$ relationship_NN to_TO prognosis_NN or_CC response_NN to_TO endocrine_JJ therapy_NN are_VBP somewhat_RB contradictory_JJ ,_, with_IN some_DT groups_NNS reporting_VBG that_IN the_DT presence_NN of_IN this_DT receptor_NN is_VBZ a_DT good_JJ prognostic_JJ factor_NN and_CC others_NNS reporting_VBG the_DT reverse_NN ._SENT There_EX are_VBP a_DT few_JJ studies_NNS on_IN PR_NP expression_NN in_IN premalignant_JJ and_CC preinvasive_JJ lesions_NNS ,_, and_CC these_DT few_JJ suggest_VBP that_DT expression_NN of_IN the_DT PR_NP also_RB increases_VBZ with_IN increasing_VBG atypia_NN ._SENT There_EX is_VBZ some_DT evidence_NN suggesting_VBG that_IN the_DT ratio_NN between_IN PRA_NP and_CC PRB_NP is_VBZ altered_VBN during_IN tumorigenesis_NN ,_, such_JJ that_IN PRA_NP predominates_VBZ ._SENT How_WRB this_DT can_MD be_VB reconciled_VBN with_IN the_DT suggestion_NN that_IN PRA_NP acts_VBZ as_IN a_DT dominant_JJ repressor_NN of_IN the_DT action_NN of_IN PRB_NP and_CC other_JJ steroid_NN receptors_NNS has_VBZ yet_RB to_TO be_VB determined_VBN ,_, but_CC these_DT data_NNS suggest_VBP that_IN alteration_NN of_IN the_DT PR_NP isoform_NN ratio_NN also_RB has_VBZ a_DT role_NN in_IN human_JJ breast_NN tumorigenesis_NN ._SENT Approximately_RB 60_CD %_NN of_IN invasive_JJ breast_NN carcinomas_NNS express_VBP PRA_NP and/or_CC PRB_NP ,_, and_CC PR_NP expression_NN is_VBZ regarded_VBN generally_RB as_IN a_DT marker_NN of_IN intact_JJ ERalpha_NP function_NN ._SENT Patients_NNS whose_WP$ tumours_NNS contain_VBP both_CC the_DT ERalpha_NP and_CC the_DT PR_NP have_VBP the_DT greatest_JJS probability_NN of_IN responding_VBG to_TO endocrine_JJ therapy_NN and_CC have_VB a_DT better_JJR prognosis_NN than_IN those_NNS whose_WP$ tumours_NNS do_VBP not_RB contain_VB steroid_NN receptors_NNS ._SENT Whether_IN the_DT PR_NP isoform_NN ratio_NN has_VBZ any_DT bearing_NN on_IN response_NN to_TO endocrine_JJ therapy_NN remains_VBZ to_TO be_VB determined_VBN ._SENT There_EX is_VBZ almost_RB complete_JJ dissociation_NN between_IN steroid_NN receptor_NN (_( ERalpha_NP and_CC PR_NP )_) expression_NN and_CC proliferation_NN in_IN the_DT normal_JJ human_JJ mammary_JJ epithelium_NN ,_, suggesting_VBG that_IN the_DT ovarian_JJ steroids_NNS oestradiol_NN and_CC progesterone_NN control_NN proliferation_NN and_CC development_NN of_IN the_DT mammary_JJ gland_NN indirectly_RB via_IN the_DT secretion_NN of_IN paracrine_JJ growth_NN factors_NNS ._SENT This_DT may_MD be_VB one_CD way_NN of_IN attenuating_VBG the_DT sensitivity_NN of_IN the_DT normal_JJ mammary_JJ epithelium_NN to_TO the_DT effects_NNS of_IN the_DT ovarian_JJ steroids_NNS and_CC of_IN ensuring_VBG that_IN significant_JJ proliferative_JJ activity_NN occurs_VBZ only_RB when_WRB it_PP is_VBZ needed_VBN (_( i.e._FW during_IN puberty_NN and_CC pregnancy_NN )_) ._SENT Increased_VBN ERalpha_NP expression_NN and_CC loss_NN of_IN the_DT inverse_JJ relationship_NN between_IN steroid_NN receptor_NN expression_NN and_CC proliferation_NN occurs_VBZ at_IN the_DT earliest_JJS stages_NNS of_IN breast_NN tumour_NN development_NN ,_, implying_VBG that_DT dysregulation_NN of_IN ERalpha_NP expression_NN is_VBZ an_DT important_JJ step_NN in_IN the_DT tumorigenic_JJ process_NN ._SENT Clearly_RB ,_, enhanced_JJ ERalpha_NP and_CC PR_NP expression_NN would_MD sensitise_VB the_DT premalignant_JJ epithelium_NN to_TO the_DT proliferative_JJ effects_NNS of_IN their_PP$ cognate_JJ ligands_NNS ,_, but_CC it_PP remains_VBZ to_TO be_VB determined_VBN whether_IN oestradiol_NN and_CC progesterone_NN continue_VBP to_TO drive_VB proliferation_NN by_IN the_DT indirect_JJ mechanisms_NNS that_WDT exist_VBP in_IN the_DT normal_JJ epithelium_NN or_CC whether_IN an_DT alternative_NN ,_, more_RBR direct_JJ ,_, pathway_NN has_VBZ arisen_VBN during_IN malignant_JJ transformation_NN ._SENT Further_JJR studies_NNS on_IN the_DT mechanisms_NNS by_IN which_WDT oestradiol_NN and_CC progesterone_NN control_NN the_DT development_NN of_IN the_DT human_JJ breast_NN and_CC breast_NN tumours_NNS could_MD lead_VB to_TO the_DT identification_NN of_IN new_JJ targets_NNS for_IN breast_NN cancer_NN prevention_NN ,_, to_TO improved_VBN prediction_NN of_IN invasive_JJ breast_NN cancer_NN risk_NN and_CC to_TO early_JJ detection_NN of_IN breast_NN tumours_NNS ._SENT DCIS_NN =_SYM ductal_JJ carcinoma_NN in_IN situ_NN ;_: ER_NP =_SYM oestrogen_NN receptor_NN ;_: PR_NP =_SYM progesterone_NN receptor_NN ;_: TDLU_NP =_SYM terminal_JJ ductal_JJ lobular_JJ unit_NN ._SENT 